INTerpath-001 results highlighted a clinically meaningful improvement when the bespoke intismeran mRNA-LNP therapy is added to pembrolizumab in cutaneous melanoma. Reporting characterizes the combination as reducing recurrence and metastasis and improving survival relative to pembrolizumab alone, marking what the update frames as a landmark Phase III win for patient-specific immunotherapy. The trial’s design—more than 1,100 participants across stage IIB–IV—supports a direct comparison between checkpoint inhibition with and without individualized mRNA. While complete endpoint details await full publication and regulatory-quality reporting, the direction of effect is the central new information conveyed in the update. If replicated in detailed analyses, the study strengthens the case for mRNA as a therapeutic modality beyond infectious disease, and for AI-guided personalization as an actionable clinical product approach.